Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

NCT03642847 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: Prevnar 13
BIOLOGICAL: multivalent pneumococcal conjugate formulation 1
BIOLOGICAL: multivalent pneumococcal conjugate formulation 2

Sponsor

Pfizer